摘要:
springer.com
sci-hub.se 参考文章(28)
T.J. Ettrich, KRAS und weitere Signalmoleküle für die Therapieentscheidung beim metastasierten Kolonkarzinom Der Gastroenterologe. ,vol. 7, pp. 24- 29 ,(2012) , 10.1007/S11377-011-0607-0
A De Gramont, A Cervantes, T Andre, A Figer, G Lledo, M Flesch, L Mineur, G Russ, E Quinaux, P-L Etienne, None, OPTIMOX study: FOLFOX 7/LV5FU2 compared to FOLFOX 4 in patients with advanced colorectal cancer Journal of Clinical Oncology. ,vol. 22, pp. 3525- 3525 ,(2004) , 10.1200/JCO.2004.22.90140.3525
Dominik P. Modest, Ruediger P. Laubender, Sebastian Stintzing, Clemens Giessen, Christoph Schulz, Michael Haas, Ulrich Mansmann, Volker Heinemann, Early tumor shrinkage in patients with metastatic colorectal cancer receiving first-line treatment with cetuximab combined with either CAPIRI or CAPOX: an analysis of the German AIO KRK 0104 trial. Acta Oncologica. ,vol. 52, pp. 956- 962 ,(2013) , 10.3109/0284186X.2012.752580
J. Tabernero, J. Tabernero, M.E. Elez, J. Capdevila, T. Macarulla, R. Gallego, 400 INVITED Strategies of Prolonged Multimodal Treatment on Metastatic Colorectal Carcinoma (mCRC): Maintenance Treatment With Targeted Agents European Journal of Cancer. ,vol. 47, ,(2011) , 10.1016/S0959-8049(11)70615-3
Y. Kuboki, T. Yoshino, K. Yamazaki, T. Nishina, Y. Komatsu, H. Baba, A. Tsuji, K. Yamaguchi, K. Muro, A. Ohtsu, 6005 ORAL A Multicenter, Randomized, Double-blind, Phase II Study of TAS-102 (A) Plus Best Supportive Care (BSC) Versus Placebo (P) Plus BSC in Patients (pts) With Chemotherapy-refractory Metastatic Colorectal Cancer (mCRC) European Journal of Cancer. ,vol. 47, ,(2011) , 10.1016/S0959-8049(11)71650-1
Al B. Benson, Stanley R. Hamilton, Path Toward Prognostication and Prediction: An Evolving Matrix Journal of Clinical Oncology. ,vol. 29, pp. 4599- 4601 ,(2011) , 10.1200/JCO.2011.37.8646
F. Andre, R. Conforti, C.B. Moeder, A. Mauguen, M. Arnedos, N. Berrada, S. Delaloge, G. Tomasic, M. Spielmann, F.J. Esteva, D.L. Rimm, S. Michiels, Association between the nuclear to cytoplasmic ratio of p27 and the efficacy of adjuvant polychemotherapy in early breast cancer Annals of Oncology. ,vol. 23, pp. 2059- 2064 ,(2012) , 10.1093/ANNONC/MDR569
Vlad Popovici, Eva Budinska, Sabine Tejpar, Scott Weinrich, Heather Estrella, Graeme Hodgson, Eric Van Cutsem, Tao Xie, Fred T. Bosman, Arnaud D. Roth, Mauro Delorenzi, Identification of a Poor-Prognosis BRAF-Mutant–Like Population of Patients With Colon Cancer Journal of Clinical Oncology. ,vol. 30, pp. 1288- 1295 ,(2012) , 10.1200/JCO.2011.39.5814
Daniel G. Haller, Josep Tabernero, Jean Maroun, Filippo de Braud, Timothy Price, Eric Van Cutsem, Mark Hill, Frank Gilberg, Karen Rittweger, Hans-Joachim Schmoll, Capecitabine Plus Oxaliplatin Compared With Fluorouracil and Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer Journal of Clinical Oncology. ,vol. 29, pp. 1465- 1471 ,(2011) , 10.1200/JCO.2010.33.6297
Carmen J Allegra, Greg Yothers, Michael J O'Connell, Saima Sharif, Linda H Colangelo, Samia H Lopa, Nicholas J Petrelli, Richard M Goldberg, James N Atkins, Thomas E Seay, Louis Fehrenbacher, Seamus O'Reilly, Luis Chu, Catherine A Azar, Norman Wolmark, None, Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer Journal of Clinical Oncology. ,vol. 27, pp. 3385- 3390 ,(2009) , 10.1200/JCO.2009.21.9220